These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38886718)

  • 61. Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation.
    Dilokthornsakul P; Nathisuwan S; Krittayaphong R; Chutinet A; Permsuwan U
    Heart Lung Circ; 2020 Mar; 29(3):390-400. PubMed ID: 31000364
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
    Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
    Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.
    Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y
    Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial.
    Qu XM; Chen Y; Zaric GS; Senan S; Olson RA; Harrow S; John-Baptiste A; Gaede S; Mulroy LA; Schellenberg D; Senthi S; Swaminath A; Kopek N; Liu M; Warner A; Rodrigues GB; Palma DA; Louie AV
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1176-1184. PubMed ID: 33309977
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding.
    Sruamsiri R; Dilokthornsakul P; Pratoomsoot C; Chaiyakunapruk N
    Pharmacoeconomics; 2014 Aug; 32(8):801-13. PubMed ID: 24849397
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cost-utility analysis of sutureless and rapid deployment versus conventional aortic valve replacement in patients with moderate to severe aortic stenosis in Thailand.
    Permsuwan U; Singhatanadgige S; Boonpipattanapong K; Slisatkorn W; Chartrungsan A; Nitayavardhana P; Luangthong N; Porapakkham P; Yadee J
    PLoS One; 2024; 19(1):e0296875. PubMed ID: 38241391
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population.
    Saokaew S; Tassaneeyakul W; Maenthaisong R; Chaiyakunapruk N
    PLoS One; 2014; 9(4):e94294. PubMed ID: 24732692
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis.
    Aungsumart S; Turongkaravee S; Youngkong S; Apiwattanakul M; Thakkinstian A; Chaikledkaew U
    BMC Health Serv Res; 2023 Oct; 23(1):1096. PubMed ID: 37833729
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Economic evaluation of endovascular treatment for acute ischaemic stroke in Thailand.
    Rattanavipapong W; Worakijthamrongchai T; Soboon B; Luankongsomchit V; Kongmuangpuk M; Isaranuwatchai W; Teerawattananon Y; Nilanont Y
    BMJ Open; 2022 Sep; 12(9):e064403. PubMed ID: 36167373
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A national quitline service and its promotion in the mass media: modelling the health gain, health equity and cost-utility.
    Nghiem N; Cleghorn CL; Leung W; Nair N; Deen FSV; Blakely T; Wilson N
    Tob Control; 2018 Jul; 27(4):434-441. PubMed ID: 28739609
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cost-effectiveness evaluation of the 45-49 year old health check versus usual care in Australian general practice: A modelling study.
    Si S; Moss J; Karnon J; Stocks N
    PLoS One; 2018; 13(11):e0207110. PubMed ID: 30412596
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
    Zafari Z; Sadatsafavi M; Marra CA; Chen W; FitzGerald JM
    PLoS One; 2016; 11(1):e0146003. PubMed ID: 26751790
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost-Utility Analysis of Early Detection with Ultrasonography of Differentiated Thyroid Cancer: A Retrospective Study on a Korean Population.
    Baek HS; Ha J; Kim K; Bae JS; Kim JS; Kim S; Lim DJ; Kim CM
    Endocrinol Metab (Seoul); 2024 Apr; 39(2):310-323. PubMed ID: 38590123
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
    Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
    Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand.
    Deerochanawong C; Krittayaphong R; Romano JGU; Rhee NA; Permsuwan U
    Diabetes Ther; 2023 Mar; 14(3):531-552. PubMed ID: 36719606
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost-Utility Analysis of Universal Maternal Pertussis Immunisation in Thailand: A Comparison of Two Model Structures.
    Botwright S; Win EM; Kapol N; Benjawan S; Teerawattananon Y
    Pharmacoeconomics; 2023 Jan; 41(1):77-91. PubMed ID: 36348154
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand.
    Kittiratchakool N; Kulpokin D; Chanjam C; Vilaiyuk S; Charuvanij S; Phongsamart G; Khaosut P; Tanya M; Nanagara R; Nantapaisarn S; Leelahavarong P
    BMJ Open; 2020 Sep; 10(9):e037588. PubMed ID: 32933962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.